PKD Trial Simulator: Insights from PKD Consortium as Tools for CKD Drug Development
- Leveraging the PKD Outcomes Consortium’s joint‐model linking longitudinal total kidney volume (TKV) growth to eGFR decline or ESRD to enrich trial populations
- Using a Clinical Trial Simulator tool to predict outcomes, design shorter or smaller trials, and optimize inclusion criteria
- Qualifying TKV as a prognostic biomarker with FDA and EMA to enable regulatory efficiency and accelerated pathways
- Integrating patient registry, natural history, and trial data into unified models for trial design and drug response prediction.